Zymergen, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zymergen, Inc. - overview
Established
2013
Location
Emeryville, CA, US
Primary Industry
Biotechnology
About
Zymergen, Inc. , based in the US, operates as a biotechnology company focused on harnessing the power of biology and technology to develop innovative materials and products for diverse industries. Zymergen, Inc. specializes in biotechnology, creating advanced materials and products through innovative biological processes.
Founded in 2013 in Emeryville, US, the company has undergone significant changes, culminating in an IPO on April 21, 2021, raising USD 500. 03 mn. The firm was co-founded by Josh Hoffman and Zach Serber, with Jay Flatley serving as CEO. Zymergen has raised a total of USD 500.
03 mn across multiple funding rounds, and its most recent funding was an IPO. In July 2022, Zymergen was acquired by Ginkgo BioWorks, Inc. for an undisclosed amount, enhancing Ginkgo's platform capabilities. Zymergen, Inc.
provides a range of biotechnology solutions aimed at various sectors, including agriculture and biopharma. The company develops innovative materials and products utilizing genetic engineering and advanced biological processes. Key offerings include AI-driven models for optimizing production, lab automation systems, and customized R&D services tailored to the specific needs of clients in the agricultural and pharmaceutical industries. Zymergen actively collaborates with firms and government agencies in North America, Europe, and parts of Asia, supporting their innovation and product development efforts.
In 2021, Zymergen, Inc. reported a revenue of USD 16. 74 mn. Despite this revenue, the company experienced a significant EBITDA loss of USD 326.
87 mn during the same year, reflecting the challenges and costs associated with its innovative biotech operations. Following its IPO on April 21, 2021, Zymergen, Inc. plans to utilize the raised USD 500. 03 mn to accelerate the production of its Hyaline film and expedite the commercialization of other products.
The company aims to expand its operations into new markets, specifically targeting regions in Asia and Europe by the end of 2023. The acquisition by Ginkgo BioWorks, completed in October 2022, is expected to further enhance Zymergen's capabilities and market reach, supporting its strategic initiatives to develop new biotechnology solutions.
Current Investors
Draper Fisher Jurvetson, True Ventures, Two Sigma
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Analytics & Performance Software, Biomaterials
Website
www.zymergen.com
Verticals
Artificial Intelligence, Artificial Intelligence, Big Data, Robotics
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Zymergen, Inc. - financials
| Fiscal Year Ended | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|
| Revenue (USD) | - | - | - |
| % Revenue Growth (YoY) | - | - | - |
| EBITDA (USD) | - | - | - |
| Operating Income (USD) | - | - | - |
| Operating Margin | - | - | - |
| % EBITDA Margin | - | - | - |
| NET Income (USD) | - | - | - |
| % Net Margin | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.